Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Olanzapine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 7/20 | 1.00 |
| ▸ | HTR2A known ✓ | P28223 | 5/20 | 1.00 |
| ▸ | HTR2C known ✓ | P28335 | 5/20 | 1.00 |
| ▸ | DRD4 known ✓ | P21917 | 4/20 | 1.00 |
| ▸ | DRD3 known ✓ | P35462 | 3/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 10/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 5/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 5/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 5/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 5/20 | 1.00 |
| ▸ | DRD1 | P21728 | 5/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 5/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 5/20 | 1.00 |
| ▸ | HRH1 | P35367 | 5/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 5/20 | 1.00 |
| ▸ | HTR2B | P41595 | 5/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 4/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 4/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 4/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 4/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Olanzapine SCHEMBL29358280 | 1.00 | CHRM1 (1.00) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL4775632 | 1.00 | CHRM1 (1.00) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL2222724 | 0.99 | CHRM1 (0.98) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL1376031 | 0.99 | CHRM1 (0.98) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL29278843 | 0.99 | CHRM1 (0.98) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL6461808 | 0.99 | CHRM1 (0.98) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL1375329 | 0.99 | CHRM1 (0.98) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL1562676 | 0.99 | CHRM1 (0.98) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL5091769 | 0.99 | CHRM1 (0.98) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL29279662 | 0.99 | CHRM1 (0.98) | CHRM1DRD2CHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 46891 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146048-A1 | NOVEL BISINDOLYLMALEIMIDE KINASE INHIBITORS | 4M THERAPEUTICS INC. (US) | 2026-05-28 | — | — | US | claimed |
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| CN-117205226-B | Application of catalpol in preparation of medicines for preventing and treating schizophrenia and relieving olanzapine glycolipid metabolism side effects | SOUTHWEST UNIVERSITY (CN) | 2026-05-26 | — | — | CN | claimed |
| CN-122079853-A | N-substituted indoles and other heterocyclic compounds for the treatment of brain diseases | — | 2026-05-26 | — | — | CN | claimed |
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| US-20260131089-A1 | DRUG DELIVERY DEVICES AND METHODS FOR ADMINISTERING SUBSTANCES TO A BODY CAVITY BY HETEROGENOUS AEROSOLIZATION FOR TREATMENT OF BINGE-EATING DISORDERS AND/OR OBESITY | APTARGROUP, INC. (US) | 2026-05-14 | — | — | US | claimed |
| US-20260132464-A1 | CIRCULAR RNAS FOR THE DIAGNOSIS AND TREATMENT OF BRAIN DISORDERS | UNM RAINFOREST INNOVATIONS (US) | 2026-05-14 | — | — | US | claimed |
| EP-4740962-A1 | PHARMACEUTICAL COMPOSITION, FORMULATION CONTAINING PHARMACEUTICAL COMPOSITION, KIT CONTAINING PHARMACEUTICAL COMPOSITION, PREPARATION METHOD FOR PHARMACEUTICAL COMPOSITION, AND USE OF PHARMACEUTICAL COMPOSITION | Shanghai WD Pharmaceutical Co., Ltd (CN) | 2026-05-13 | — | — | EP | claimed |
| CN-122029214-A | Phospholipid drug conjugate and preparation method and application thereof | 上海弼领生物技术有限公司 | 2026-05-12 | — | — | CN | claimed |
| EP-0738515-A1 | Treatment of nicotine withdrawal | ELI LILLY AND COMPANY (US) | 1996-10-23 | — | — | EP | claimed |
| WO-1996031621-A2 | METHOD FOR DETERMINING THE RESPONSIVENESS OF INDIVIDUALS TO 5-HT2 RECEPTOR MODULATING AGENTS | SMITHKLINE BEECHAM PLC (GB) | 1996-10-10 | — | — | WO | claimed |
| WO-1996030375-A1 | PROCESS AND CRYSTAL FORMS OF 2-METHYL-THIENO-BENZODIAZEPINE | ELI LILLY AND COMPANY (US) | 1996-10-03 | — | — | WO | claimed |
| WO-1996029995-A1 | ORAL 2-METHYL-THIENO-BENZODIAZEPINE FORMULATION | ELI LILLY AND COMPANY (US) | 1996-10-03 | — | — | WO | claimed |
| WO-1996030374-A1 | PROCESS FOR PREPARING OLANZAPINE | ELI LILLY AND COMPANY (US) | 1996-10-03 | — | — | WO | claimed |
| EP-0733367-A1 | Oral olanzapine formulation | ELI LILLY AND COMPANY (US) | 1996-09-25 | — | — | EP | claimed |
| EP-0733635-A1 | Crystal forms of a thieno(2,3-B)(1,5) benzodiazepine derivative and process for their preparation | ELI LILLY AND COMPANY (US) | 1996-09-25 | — | — | EP | claimed |
| EP-0733368-A1 | Granule fomulation for olanzapine | ELI LILLY AND COMPANY (US) | 1996-09-25 | — | — | EP | claimed |
| EP-0733634-A1 | Process for preparing a thieno(2,3-B)(1,5) benzodiazepine derivative | ELI LILLY AND COMPANY (US) | 1996-09-25 | — | — | EP | claimed |
| US-5457101-A | For gastrointestinal disorders; irritable bowel syndrome | ELI LILLY AND COMPANY (US) | 1995-10-10 | — | — | US | claimed |